CSL Ltd. — M&A Activity 2008

Oct 12, 2008

For immediate release October 13, 2008

==> picture [205 x 32] intentionally omitted <==

==> picture [59 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics

Melbourne, Australia – October 13, 2008 – CSL Limited today announced that it has received a request for additional information, commonly referred to as a Second Request, from the U.S. Federal Trade Commission (“FTC”) regarding its proposed acquisition of Talecris Biotherapeutics, which was announced on August 13, 2008. CSL intends to respond expeditiously to the Second Request.

CSL advised that the FTC has not yet reached any conclusions regarding the proposed acquisition and the request for additional information from the FTC is a normal part of the U.S. regulatory review process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”).

CSL and Talecris are co-operating with the FTC to respond to the request and obtain the necessary regulatory approvals to secure timely closure of the acquisition.

Media Contact: Dr Rachel David Director, Public Affairs Ph 61 3 9389 1821 Email: rachel.david@csl.com.au

Investor Contact:

Mark Dehring Director, Investor Relations Phone: 61 3 9389 2818 Email: mark.dehring@csl.com.au

==> picture [98 x 7] intentionally omitted <==